SHOULDER INNOVATIONS, INC. (SI) FY2025 10-K Annual Report
SHOULDER INNOVATIONS, INC. (SI) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Mar 10, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
SHOULDER INNOVATIONS, INC. FY2025 10-K Analysis
Business Overview
- • Medical technology company focused exclusively on shoulder surgical care with integrated ecosystem including implants, AI-based preoperative planning, and specialized support
- • New product launches in 2025-2026: InSet 70 humeral stem, metal sensitivity implants (FDA cleared Jan 2026), and development of a shoulder-specific robotics platform integrating with ProVoyance
- • Strategic emphasis on ambulatory surgery centers (ASCs) growth, leveraging streamlined two-tray instrument system to improve efficiency and cost-effectiveness vs traditional hospital settings
- • Procedure volume increased 50% from 2024 to 2025, implants utilized in over 17,500 surgeries since 2016, 45 dedicated shoulder specialists with 750+ years combined experience in commercial and clinical education roles
- • Long-term clinical data highlights InSet Glenoid’s 8.7-year mean follow-up with no loosening, revision, or surgical complications, supporting implant longevity and differentiation in shoulder arthroplasty
Risk Factors
- • Regulatory risk: CMS added total shoulder arthroplasty to ASC covered procedures list effective Jan 1, 2024, impacting Medicare reimbursement and ASC demand
- • Geopolitical/macro risk: No specific geopolitical risk disclosed; next material: seasonality with Q3 demand decline due to summer lifestyle impact
- • Operational risk: Dependency on third-party U.S. manufacturers for implant production, requiring inventory scaling to meet growing demand
- • Competitive risk: Growth tied to ASC procedures outpacing hospital settings, facing downward pricing pressure in medical services industry
- • Financial risk: $15M term loan with 11% minimum interest, tranche availability contingent on $45M annualized revenue by Dec 31, 2026
SHOULDER INNOVATIONS, INC. FY2025 Key Financial MetricsXBRL
Revenue
$47M
▲ +49.6% YoY
Net Income
-$40M
▼ -158.4% YoY
Gross Margin
76.5%
▼ -46bp YoY
Operating Margin
-55.6%
▼ -924bp YoY
Net Margin
-85.3%
▼ -3590bp YoY
ROE
-28.7%
▼ -5723bp YoY
Total Assets
$170M
▲ +294.4% YoY
EPS (Diluted)
$-4.65
▲ +98.1% YoY
Operating Cash Flow
-$29M
▼ -102.3% YoY
Source: XBRL data from SHOULDER INNOVATIONS, INC. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on SHOULDER INNOVATIONS, INC.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.